ANRONYSEPharmaceutical PreparationsFiscal year ends December 31
Alto Neuroscience, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$22.82+0.88 (+4.01%)
Close on Oct 19, 2026
- Market cap
- $976.99M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
75.1%
29M of 39M shares
Institutional holders
114
27 new, 22 sold out
Net institutional buying
3M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Perceptive Life Sciences Master Fund, Ltd. | 4,176,711 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| Chimera Investment LLC | 3,707,757 | 13.80% | 13G (passive) | Feb 6, 2024 |
| Michael Kramarz | 3,588,180 | 9.90% | 13G (passive) amendment | Mar 31, 2026 |
| Commodore Capital Master LP | 3,245,628 | 9.90% | 13G (passive) amendment | Dec 31, 2025 |
| Robert Egen Atkinson | 3,190,267 | 9.80% | 13G (passive) | Oct 20, 2025 |
| Sirenia Capital Management LP | 2,591,587 | 7.90% | 13G (passive) | Mar 31, 2026 |
| EcoR1 Capital, LLC | 2,232,000 | 5.80% | 13G (passive) | Jul 13, 2026 |
| Alex Silverstein | 2,219,568 | 6.20% | 13G (passive) amendment | Jun 30, 2026 |
| BlackRock, Inc. | 2,104,406 | 6.00% | 13G (passive) | Jun 30, 2026 |
| Vestal Point Capital, LP | 2,064,075 | 6.50% | 13G (passive) amendment | Mar 31, 2026 |
| Joseph Edelman | 1,989,393 | 7.30% | 13G (passive) | Oct 3, 2025 |
| Anup Arora | 1,617,855 | 5.60% | 13G (passive) | Jan 13, 2025 |
| Amit Etkin | 1,461,130 | 5.40% | 13G (passive) | Sep 30, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ANRO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Alpha Wave Global, LP | 3,707,757 | 9.45% | $97.85M | – | 1.57% |
| Commodore Capital LP | 2,723,196 | 6.94% | $71.87M | – | 4.28% |
| BlackRock, Inc. | 2,121,009 | 5.40% | $55.97M | +1,454,821 | 0.00% |
| Perceptive Advisors LLC | 1,609,893 | 4.10% | $42.49M | −400,000 | 0.64% |
| Adage Capital Partners Gp, L.L.C. | 1,600,000 | 4.08% | $42.22M | +1,215,000 | 0.06% |
| Vanguard Capital Management LLC | 1,389,477 | 3.54% | $36.67M | +182,452 | 0.00% |
| Spruce Street Capital LP | 1,353,047 | 3.45% | $35.71M | +27,837 | 7.01% |
| Vivo Capital, LLC | 1,208,858 | 3.08% | $31.90M | +173,307 | 2.91% |
| Franklin Resources Inc | 1,013,307 | 2.58% | $26.74M | −88,567 | 0.01% |
| Armistice Capital, LLC | 864,000 | 2.20% | $22.80M | −48,000 | 0.28% |
| Affinity Asset Advisors, LLC | 850,000 | 2.17% | $22.43M | +350,000 | 1.01% |
| Vestal Point Capital, LP | 785,000 | 2.00% | $20.72M | −1,279,075 | 0.48% |
| State Street Corp | 685,945 | 1.75% | $18.10M | +486,442 | 0.00% |
| Geode Capital Management, LLC | 678,199 | 1.73% | $17.90M | +385,300 | 0.00% |
| 72 Investment Holdings, LLC | 667,778 | 1.70% | $17.62M | – | 35.27% |
| Northern Trust Corp | 632,701 | 1.61% | $16.70M | +159,298 | 0.00% |
| Millennium Management LLC | 558,320 | 1.42% | $14.73M | −263,662 | 0.01% |
| Point72 Asset Management, L.P. | 502,950 | 1.28% | $13.27M | −137 | 0.01% |
| Integral Health Asset Management, LLC | 500,000 | 1.27% | $13.20M | – | 0.52% |
| VR Adviser, LLC | 500,000 | 1.27% | $13.20M | – | 0.40% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 114 | 29M | 75.1% | 27 / 39 | 27 / 22 | 6M | 4M |
| Q1 2026 | 110 | 27M | 68.4% | 25 / 27 | 43 / 10 | 7M | 4M |
| Q4 2025 | 97 | 24M | 62.4% | 30 / 27 | 25 / 9 | 9M | 2M |
| Q3 2025 | 77 | 17M | 43.2% | 9 / 19 | 26 / 12 | 1M | 1M |
| Q2 2025 | 80 | 17M | 44.1% | 20 / 21 | 23 / 23 | 2M | 5M |
| Q1 2025 | 83 | 21M | 53.1% | 20 / 18 | 27 / 12 | 2M | 3M |
| Q4 2024 | 77 | 23M | 57.4% | 24 / 31 | 10 / 22 | 7M | 8M |
| Q3 2024 | 75 | 23M | 58.5% | 23 / 35 | 9 / 5 | 6M | 1M |
| Q2 2024 | 58 | 19M | 47.4% | 18 / 20 | 12 / 13 | 3M | 1M |
| Q1 2024 | 53 | 16M | 40.9% | 53 / 0 | 0 / 0 | 16M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ANRO | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,011,881 | 2.58% | $26.70M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 663,352 | 1.69% | $17.51M | 0.02% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 346,618 | 0.88% | $9.15M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 287,033 | 0.73% | $7.77M | 0.02% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 240,404 | 0.61% | $6.34M | 0.04% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 228,057 | 0.58% | $6.02M | 0.05% | Jun 30, 2026 |
| iShares Biotechnology ETF | 221,513 | 0.56% | $5.85M | 0.06% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 190,203 | 0.48% | $5.02M | 1.17% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund | 182,834 | 0.47% | $4.95M | 0.43% | Jul 31, 2026 |
| Franklin Biotechnology Discovery Fund | 165,070 | 0.42% | $4.47M | 0.39% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 138,181 | 0.35% | $2.77M | 0.01% | May 31, 2026 |
| iShares Micro-Cap ETF | 88,048 | 0.22% | $2.32M | 0.15% | Jun 30, 2026 |
| AdvisorShares Psychedelics ETF | 70,748 | 0.18% | $1.87M | 4.20% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 63,570 | 0.16% | $1.72M | 0.02% | Jul 31, 2026 |
| Master Small Cap Index Series | 48,959 | 0.12% | $1.29M | 0.02% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Amit Etkin | PRESIDENT AND CEO, Director | 833,949 | 2.13% | May 15, 2026 |
| Nicholas Conrad Smith | CHIEF FINANCIAL OFFICER & CBO | 24,060 | 0.06% | Mar 3, 2026 |
| Adam Savitz | CHIEF MEDICAL OFFICER | 39,851 | 0.10% | Feb 13, 2026 |
| Jr. Michael Conick Hanley | CHIEF OPERATING OFFICER | – | – | Feb 13, 2026 |
| Andrew Craig Miller | Director | – | – | May 29, 2026 |
| Gwill York | Director | 23,917 | 0.06% | May 14, 2026 |
| Christopher Nixon Cox | Director | 588,898 | 1.50% | May 14, 2026 |
| Andrew Dreyfus | Director | – | – | May 14, 2026 |
| Husseini Manji | Director | – | – | May 14, 2026 |
| Ramiro Sanchez | Director | – | – | May 14, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Amit Etkin PRESIDENT AND CEO, Director | May 14, 2026 | Gift | −400,000 | – | – | 833,949 |
| Nicholas Conrad Smith CHIEF FINANCIAL OFFICER & CBO | Mar 1, 2026 | Tax withholding | −2,806 | $19.69 | $55.25K | 24,060 |
| Amit Etkin PRESIDENT AND CEO, Director | Mar 1, 2026 | Tax withholding | −6,227 | $19.69 | $122.61K | 1,233,949 |
| Adam Savitz CHIEF MEDICAL OFFICER | Jul 10, 2024 | Buy | +2,931 | $13.22 | $38.75K | 39,851 |
| Adam Savitz CHIEF MEDICAL OFFICER | Jul 9, 2024 | Buy | +1,388 | $13.15 | $18.25K | 36,920 |
| Adam Savitz CHIEF MEDICAL OFFICER | Jul 9, 2024 | Buy | +10,681 | $12.53 | $133.83K | 35,532 |
| Nicholas Conrad Smith CHIEF FINANCIAL OFFICER | Mar 28, 2024 | Buy | +4,550 | $16.56 | $75.35K | 26,866 |
| Nicholas Conrad Smith CHIEF FINANCIAL OFFICER | Mar 28, 2024 | Buy | +1,600 | $15.80 | $25.28K | 22,316 |
| Nicholas Conrad Smith CHIEF FINANCIAL OFFICER | Mar 1, 2024 | Award | +19,153 | – | – | 20,716 |
| Amit Etkin PRESIDENT AND CEO, Director | Mar 1, 2024 | Award | +34,711 | – | – | 1,240,176 |
| Investment Group Ltd. Apeiron – | Feb 6, 2024 | Conversion | +251,881 | – | – | 251,881 |
| Investment Group Ltd. Apeiron – | Feb 6, 2024 | Conversion | +674,658 | – | – | 674,658 |
| Alpha Wave Global, LP 10% owner | Feb 6, 2024 | Conversion | +1,962,995 | – | – | 1,962,995 |
| Alpha Wave Global, LP 10% owner | Feb 6, 2024 | Conversion | +1,144,762 | – | – | 3,107,757 |
| Alpha Wave Global, LP 10% owner | Feb 6, 2024 | Buy | +600,000 | $16.00 | $9.60M | 3,707,757 |
| Adam Savitz CHIEF MEDICAL OFFICER | Feb 6, 2024 | Conversion | +7,851 | – | – | 7,851 |
| Adam Savitz CHIEF MEDICAL OFFICER | Feb 6, 2024 | Buy | +17,000 | $16.00 | $272.00K | 24,851 |
| Gwill York Director | Feb 6, 2024 | Conversion | +23,917 | – | – | 23,917 |
| Po Yu (Jeff) Chen Director | Feb 6, 2024 | Conversion | +39,259 | – | – | 39,259 |
| Po Yu (Jeff) Chen Director | Feb 6, 2024 | Conversion | +8,450 | – | – | 47,709 |
| Amit Etkin PRESIDENT AND CEO, Director | Feb 6, 2024 | Conversion | +11,777 | – | – | 1,202,340 |
| Amit Etkin PRESIDENT AND CEO, Director | Feb 6, 2024 | Buy | +3,125 | $16.00 | $50.00K | 1,205,465 |
| Christopher Nixon Cox Director | Feb 6, 2024 | Conversion | +588,898 | – | – | 588,898 |
| Christopher Nixon Cox Director | Feb 6, 2024 | Conversion | +126,755 | – | – | 715,653 |
| Nicholas Conrad Smith CHIEF FINANCIAL OFFICER | Feb 6, 2024 | Buy | +1,563 | $16.00 | $25.01K | 1,563 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Smith Nicholas Officer | Sep 29, 2026 | 134,886 | $3.60M | Sep 29, 2026 | Exercise of Stock Options |